• Capricor Therapeutics disclosed new 24-month HOPE-3 open-label extension data on deramiocel in Duchenne muscular dystrophy.
• Results were presented at the 2026 World Muscle Society Congress; a patient-focused webinar is set for Oct. 7, 2026.
• Patients who switched from placebo to deramiocel showed a marked slowdown in upper-limb functional decline versus their prior year.
• Two-year data in both study groups indicated slower deterioration than expected from untreated disease progression.
• Data were added to deramiocel’s BLA; FDA action is due by the Nov. 22, 2026 PDUFA target date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050900PRIMZONEFULLFEED9839308) on October 05, 2026, and is solely responsible for the information contained therein.